The estimated Net Worth of Craig A Collard is at least $23.9 Milion dollars as of 19 July 2024. Mr. Collard owns over 13,797 units of Opiant Pharmaceuticals Inc stock worth over $5,711,584 and over the last 16 years he sold OPNT stock worth over $18,217,156. In addition, he makes $0 as Independent Director at Opiant Pharmaceuticals Inc.
Sign up
Mr. Collard OPNT stock SEC Form 4 insiders trading
Craig has made over 13 trades of the Opiant Pharmaceuticals Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 13,797 units of OPNT stock worth $284,908 on 19 July 2024.
The largest trade he's ever made was selling 1,443,913 units of Opiant Pharmaceuticals Inc stock on 3 April 2012 worth over $9,024,456. On average, Craig trades about 105,660 units every 171 days since 2008. As of 19 July 2024 he still owns at least 276,590 units of Opiant Pharmaceuticals Inc stock.
You can see the complete history of Mr. Collard stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Craig Collard biography
Craig Alexander Collard is Independent Director of the Company. Mr. Collard has served as the Chief Executive Officer of Veloxis Pharmaceutics, Inc., or Veloxis, since December 2015. Prior to joining Veloxis, he served as the Chief Executive Officer and the chairman of the Board of Directors Cornerstone Therapeutics, Inc., or Cornerstone, until February 2014, when Cornerstone was purchased by Chiesi Pharmaceuticals, Inc. He also served as Cornerstone’s Interim Chief Financial Officer from July 2010 through January 2011 and its President from October 2008 to September 2011. In March 2004, Mr. Collard founded Cornerstone BioPharma Holdings, Ltd. (the assets and operations of which were restructured as Cornerstone BioPharma in May 2005), and served as its President and Chief Executive Officer and a director from March 2004 to October 2008. Before founding Cornerstone BioPharma, Mr. Collard’s principal occupation was serving as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company he founded in May 2003. From August 2002 to February 2003, Mr. Collard served as Vice President of Sales for Verum Pharmaceuticals, Inc., a specialty pharmaceutical company in Research Triangle Park, North Carolina. From 1998 to 2002, Mr. Collard worked as Director of National Accounts at DJ Pharma, Inc., a specialty pharmaceutical company which was eventually purchased by Biovail Pharmaceuticals, Inc., or Biovail. His pharmaceutical career began in 1992 as a field sales representative at Dura Pharmaceuticals, Inc., or Dura. He was later promoted to several other sales and marketing positions within Dura. Mr. Collard is a member of the Board of Directors of Biomark Pharmaceuticals, Inc., a biopharmaceutical company in Durham, North Carolina, Hilltop Home Foundation, a Raleigh, North Carolina, non-profit corporation, as well as the Triangle Chapter of the Cystic Fibrosis Foundation. Mr. Collard holds a B.S. in Engineering from the Southern College of Technology, in Marietta, Georgia
What's Craig Collard's mailing address?
Craig's mailing address filed with the SEC is 4242 CAMPUS POINT COURT, SUITE 200, , SAN DIEGO, CA, 92121.
Insiders trading at Opiant Pharmaceuticals Inc
Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen a Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.
What does Opiant Pharmaceuticals Inc do?
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
What does Opiant Pharmaceuticals Inc's logo look like?
Complete history of Mr. Collard stock trades at Heron Therapeutics Inc, Sierra Oncology Inc, Opiant Pharmaceuticals Inc a Cortexyme Inc
Opiant Pharmaceuticals Inc executives and stock owners
Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Roger Crystal,
President, Chief Executive Officer, Director -
Michael Sinclair,
Executive Chairman of the Board -
Dr. Roger Crystal,
Pres, CEO & Director -
Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
Chief Scientific Officer -
David D. O'Toole,
Chief Financial Officer -
Michael Porter,
IR Contact Officer -
Richard Daly,
Independent Director -
Craig Collard,
Independent Director -
Thomas Thomas,
Director -
Gabrielle Silver,
Director -
Ann MacDougall,
Director -
Aziz Mottiwala,
Chief Commercial Officer -
Rahsaan Thompson,
General Counsel -
Phil Skolnick,
Chief Scientific Officer -
Arvind Agrawal,
Executive Vice President - Medical Affairs -
David O'Toole,
Chief Financial Officer -
Matthew R. Ruth,
Chief Commercial Officer -
Dr. Mark Heath Ellison Ph.D.,
Chief Devel. Officer -
Brian Gorman,
EVP Corp. Devel. & Gen. Counsel -
Ben Atkins,
VP of Communications & Investor Relations -
Matthew R. Ruth,
Chief Commercial Officer -
Ronald W Kaiser,
Director -
Melvin Iii Wesley,
Chief Financial Officer -
William F Stasior,
Director -
Steven G Finn,
Director -
Joseph W Kuhn,
VP & Chief Financial Officer -
Alain J Cohen,
President & Chief Tech Officer -
Marc A Cohen,
Chairman, CEO, Treas, & Sec -
Brian Gorman,
-
Mark Jason Heath Ellison,
Chief Development Officer -
Masuoka K. Lorianne,
Director